Current Clinical Trials

For enquiries, please email [email protected]

Phase 1

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	NSCLC, Pancreas and all solid tumors	IV	MCLA-128-CL01 A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors	Dr Justina Lam	NCT02912949	Open
2	All Solid Tumour	Advanced recurrent	TAPISTRY Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial	Dr Tira Tan	NCT04589845	Open
3	NSCLC	Advanced recurrent	Bayer 21607 An open label, first-in-human study of BAY 2927088 in participants with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation	Dr Daniel Tan	NCT05099172	Open
4	HCC	Advanced recurrent	SCG 101-UR-103 A Phase I/ IIa, single arm, multicenter study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma	Dr Toh Han Chong	NCT05417932	On hold
5	HCC (positive GPC3 expression )	Recurrent/ Metastatic	TCD17240 A Phase 1/2 open-label, first-in-human, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR444200-based regimen in participants with advanced solid tumors	Dr Darren Lim	NCT05450562	On hold
6	All solid tumours	Prior IO responders	BAYER 21820 First-in-human dose-escalation and expansion study of the anti-CCR8 antibody BAY 3375968 in combination with pembrolizumab to evaluate the safety, tolerability, and pharmacokinetics in participants with selected advanced solid tumors	Dr Tira Tan	NCT05537740	Open
7	HCC	1st line HCC	BMS CA224-106 A Phase 1/2, Safety Confirmation and Double-Blind, Randomized Study of Relatlimab in Combination with Nivolumab and Bevacizumab in Treatment-Naive Advanced/Metastatic Hepatocellular Carcinoma (RELATIVITY-106)	Dr David Tai	NCT05337137	Closing
8	All solid tumors & Stage B/C HCC	MYC oncogene	OTX-2002-101 A Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor	Dr David Tai	NCT05497453	On hold
9	All solid tumours	KRAS G12Cmut	RMC-6291-001 Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors	Dr Daniel Tan	NCT05462717	On hold
10	NSCLC, PDAC and GC	Advanced recurrent	EBC-129-01 A Phase 1A/B Study To Evaluate The Safety And Tolerability Of EBC-129 As A Single Agent And In Combination With Pembrolizumab In Advanced Solid Tumours	Dr Matthew Ng	NCT05701527	Open
11	NSCLC/ all solid tumours	ROS-1 positive	NVL-520-01 A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)	Dr Daniel Tan	NCT05118789	Open
12	HNSCC	Advanced or recurrent	ALE.CO4.01 Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti- PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma	Dr Darren Lim	NCT06054477	Open
13	All solid tumors	SMARCA4 mutation	PRT3789-01 A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation	Dr Daniel Tan	NCT05639751	Open
14	NSCLC / lung, all solid tumours	Advanced recurrent	NVL-655-01 A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)	Dr Aaron Tan	NCT05384626	Open
15	Pancreatic / GI	Advanced, Metastatic / stage 4 / stage IV	PAUF-I A First in human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients with Advanced/Metastatic Pancreatic Cancer	Dr David Tai	NCT05141149	Open
16	Breast	Advanced, Metastatic / stage 4 / stage IV	CAAA603D12101 A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor	Dr Yap Yoon Sim	NCT06247995	Open
17	All solid tumours	Advanced, Metastatic / stage 4 / stage IV	PMV-586-101 A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)	Dr Tira Tan	NCT04585750	Open

Current clinical trials by body parts

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	Biliary Tract	Advanced 1st line	TOURMALINE D4191C00140 A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers	Dr David Tai	NCT05771480	On hold
2	Bladder / GU	Metastatic	SGNDV-001 An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)	Dr Ravindran Kanesvaran	NCT05911295	Open
3	Breast	Mets TNBC	BEXMET Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells from a Mesenchymal-Like to an Epithelial-Like Phenotype	Dr Elaine Lim	NCT04664829	Open
4	Breast	Mets ER+PR+	LaPemERLA Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer with Letrozole in the Advanced setting – a Phase II Study	Dr Yap Yoon Sim	NCT05286437	Open
5	Breast	Mets ER+PR+	ELEVATE A Phase II randomized trial of Endocrine therapy Letrozole and Lenvatinib versus Fulvestrant in Metastatic Estrogen Receptor positive, HER2 negative breast cancer, who have progressed on CDK4/6 inhibitors	Dr Elaine Lim	NCT05181033	Open
6	Breast	Mets HER2+/ PIK3CA mutant	INAVO122: A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study evaluating the Efficacy and Safety of Inavolisib in Combination with Phesgo versus Placebo in Combination with Phesgo after First Line Induction Therapy in Participants with PIK3CA-mutated HER2-positive Locally Advanced or Metastatic Breast Cancer	Dr Yap Yoon Sim	NCT05894239	Open
7	Breast	early stage I-III TNBC or HR/HER2 low	TROPION-Breast04: A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato‑DXd) Plus Durvalumab and Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy and Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or HR‑low/HER2-negative Breast Cancer	Dr Rebecca Dent	NCT06112379	Open
8	Breast	Mets HER2-/HR+ 1L Hormone resistant	CO44657 A phase III randomized, open-label study evaluating efficacy and safety of giredestrant compared with fulvestrant, both combined with a CDK4/6 inhibitor, in patients with Estrogen Receptor-positive, HER2-negative advanced breast cancer with resistance to prior adjuvant endocrine therapy	Dr Yap Yoon Sim	NCT06065748	Open
9	Breast	ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence	J2J-MC-JZLH / EMBER-4 A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence	Dr Yap Yoon Sim	NCT05514054	Open
10	Cervical	metastatic	MK2870-20 A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-Line or Third-Line Treatment for Participants with Recurrent or Metastatic Cervical Cancer	Dr Chay Wen Yee	NCT06459180	Open
11	Colorectal	Neoadjuvant	OTSP-WoOCRC / MK-3475-886 Window of Opportunity Study with Neoadjuvant Pembrolizumab in MSS & MSI Colorectal Cancer	Dr Iain Tan	NCT03984578	Open
12	Endometrial	Metastatic	MK2870-005 A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants with Endometrial Cancer Who Have Receive Prior Platinum-based Chemotherapy and Immunotherapy	Dr Jack Chan	NCT06132958	Open
13	Esophageal	Metastasis 1st line	A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma	Dr Justina Lam	NCT04949256	Open
14	Gastric GEJ	Advanced 2nd and 3rd line	ASPEN-06 A Phase 2/3 Study of ALX148 In Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma	Dr Matthew Ng	NCT05002127	On hold
15	Liver cancer or Colorectal cancer with liver metastases	Adjuvant	CA209-7R9 An open label, single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) vaccine and anti-PD1 (Nivolumab) as adjuvant treatment in resected hepatocellular carcinoma (HCC) (Group A) and liver metastases from colorectal cancer (CRLM) (Group B)	Dr Koo Si Lin	NCT04912765	Open
16	Liver	Locally advanced	AHCC09 A Multinational, Double-blind, Placebo-Controlled, Parallel Randomized Arms, Phase II trial to Compare the Safety and Efficacy of Selective Internal Radiation Therapy (Y-90 resin microspheres) followed by Atezolizumab plus Bevacizumab versus Selective Internal Radiation Therapy (SIRT-Y90) followed by placebo in patients with locally advanced Hepatocellular Carcinoma	Dr Toh Han Chong	NCT05377034	Open
17	Liver	Resectable HCC (high risk of recurrence)	AHCC12 Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab plus Bevacizumab in Resected Hepatocellular Carcinoma (HCC)	Dr Toh Han Chong	NCT05516628	Open
18	Liver	1st line advanced/ mets HCC	SIERRA A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma	Dr Joycelyn Lee	NCT05883644	Open
19	NSCLC / Lung	Locally Advanced, Unresectable, Stage III / stage 3 NSCLC	BO42777 (HORIZON01) A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)	Dr Darren Lim	NCT05170204	Open
20	NSCLC / Lung	locally advanced / metastatic / Mets NSCLC, stage 4/ stage IV	BGB-LC-201 A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination with Investigational Agents With or Without Chemotherapy in Patients with Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer	Dr Darren Lim	NCT05635708	Open
21	NSCLC / Lung	newly diagnosed locally advanced (clinical stage 3b / IIIB, 3c / IIIC)/ metastatic NSCLC (clinical stage 4 / IVA or IVB) / recurrent non-squamous NSCLC	A Phase II, Open-label, Single-arm, Multi-centre Study to Evaluate the Safety and Efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (OSTARA)	Dr Daniel Tan	NCT05801029	Open
22	NSCLC / Lung	locally advanced / metastatic / Mets NSCLC, stage 4/ stage IV	FURMO 004 AN OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS	Dr Gillianne Lai	NCT05607550	Open
23	NSCLC / Lung	Mets NSCLC	SOS-1 / IIT-SIN-S1-2022-001 A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR mutant NSCLC	Dr Darren Lim	NCT05773092	Open
24	NSCLC / Lung	Mets NSCLC	BI 1479-0008 (BEAMION LUNG-02) A Phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations	Dr Stephanie Saw	NCT06151574	Open
25	NSCLC / Lung	Mets NSCLC	HMBD-001-103 A Phase 1b Study to Evaluate HMBD-001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers	Dr Aaron Tan	NCT05910827	Open
26	NSCLC / Lung	Mets NSCLC	A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)	Dr Stephanie Saw	NCT05261399	Open
27	SCLC / Lung	Limited-Stage Small-Cell Lung Cancer	20230016 A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306)	Dr Amit Jain	NCT06117774	Open
28	Lymphoma	Relapsed/Refractory EBV+ Lymphomas	VT3996-202 An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Subjects with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)	Dr Nagavalli Somsundaram	NCT05011058	Open
29	Lymphoma	Relapsed/ Refractory B-cell lymphoma	MK2140-006 A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies	Dr Tan Ya Hwee	NCT05458297	Open
30	Lymphoma	relapsed/ refractory Lymphoma	POLAR Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma (POLAR)	Dr Lim Soon Thye	NCT06160843	Open
31	Lymphoma	Untreated DLBCL	R1979-ONC-2105 A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an anti CD20 × anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)	Dr Ong Shin Yeu	NCT06091865	Open
32	Lymphoma	relapsed/ refractory lymphoma	R1979-HM-2299 A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, versus Standard of Care Therapy in Participants with Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma (OLYMPIA-4)	Dr Lawrence Ng	NCT06230224	Open
33	NPC	Metastatic, 3rd line	SG-AAA-II-01 / CAAA601A0SG01T A Biomarker Enrichment Phase II study of 177Lu-DOTATATE in Metastatic Nasopharyngeal Cancer with a safety run-in	Dr Daniel Tan	NCT05198479	Open
34	Ovarian	Metastatic	STRO-002-GM2: A phase II open-label study evaluating the efficacy and safety of STRO-002 in women with advanced, relapsed platinum resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) expressing Folate Receptor alpha (FolRα)	Dr Elaine Lim	NCT05870748	Open
35	Pancreas	Metastatic, any line	LDOXIRI-PDAC-01 A phase II study of metronomic capecitabine, oxaliplatin and UGT1A1 genotype-directed irinotecan in metastatic pancreatic cancer patients	Dr Joycelyn Lee	NCT05929885	Open
36	Prostate	Metastatic	CAAA617D12302 An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)	Dr Jeffery Tuan	NCT05939414	Open
37	Prostate	Metastatic/ mCRPC	MK-5684-003 A Phase 3 Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy	Dr Ravindran Kanesvaran	NCT06136624	Open
38	Prostate	Metastatic/ mCRPC	MK5684-004 A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA)	Dr Johan Chan	NCT06136650	Open
39	Renal	Locally advanced / metastatic - 1st line	XL092-304 A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma	Dr Ravindran Kanesvaran	NCT05678673	Open

General

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards	APL10101 Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Dr Gillianne Lai	NCT03175224	Open
2	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards	TPX-0005-01 A Phase 1/2, Open-Label, Multi-Center, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1)	Dr Darren Lim	NCT03093116	Open
3	SOLID TUMORS (currently only HCC and gastric cohorts are opened)	Advanced curatively unresectable solid tumors failing standard therapy. HCC: must have failed at least 1 line of standard therapy Gastric cancer: must have failed at least 2 line of standard therapy (inclusive of adjuvant treatment) Other solid tumours: must have failed at least 1 line of standard therapy	NCCS-2018-Phase2-PRL3 An open label Phase II study of the efficacy and tolerability of PRL3-ZUMAB and predictive biomarkers in advanced solid tumours	Dr Matthew Ng	NCT04118114	Open
4	SOLID TUMORS	ADVANCED/ METASTATIC - 2nd Line	STCC-01 A phase II multi-centre study evaluating the efficacy of dacomitinib for patients with epidermal growth factor receptor (EGFR)-driven advanced solid tumours with low EGFR-AS1 lncRNA expression or other novel emerging biomarkers	Dr Daniel Tan	NCT04946968	Open
5	SOLID TUMORS	ADVANCED/ METASTATIC	Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α related Genetic Alterations	Dr Joanne Ngeow	NCT04924075	Open

Current Clinical Trials

​For enquiries, please email [email protected]

Phase 1

Current clinical trials by body parts

General

For enquiries, please email [email protected]